CDC Logo Tuberculosis Information CD-ROM   Image of people
     
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

 

U.S. Department of Health and Human Services

  
jump over right navigation bar
TB Notes 1, 2000
Introduction
Where We've Been and Where We're Going: Perspectives from CDC's Partners in TB Control
Changes I've Seen
TB Control in New York City: A Recent History
Not by DOT Alone
Baltimore at the New Millennium
From Crickets to Condoms and Beyond
The Denver TB Program: Opportunity, Creativity, Persistence, and Luck
National Jewish: The 100-Year War Against TB
Earthquakes, Population Growth, and TB in Los Angeles County
TB in Alaska
CDC and the American Lung Association/ American Thoracic Society: an Enduring Public/Private Partnership
The Unusual Suspects
The Model TB Prevention and Control Centers: History and Purpose
My Perspective on TB Control over the Past Two to Three Decades
History of the IUATLD
Thoughts about the Future of TB Control in the United States
Where We've Been and Where We're Going: Perspectives from CDC
Early History of the CDC TB Division, 1944-1985
CDC Funding for TB Prevention and Control
Managed Care and TB Control - A New Era
Early Research Activities of the TB Control Division
The First TB Drug Clinical Trials
Current TB Drug Trials: The Tuberculosis Trials Consortium (TBTC)
TB Communications and Education
TB Control in the Information Age
Field Services Activities
TB's Public Health Heroes
Infection Control Issues
A Decade of Notable TB Outbreaks: A Selected Review
International Activities
The Role of CDC's Division of Quarantine in the Fight Against TB in the U.S.
The STOP TB Initiative, A Global Partnership
Seize the Moment - Personal Reflections
 
Return to Table of Contents

This is an archived document. The links are no longer being updated.

TB Notes 1, 2000

National Jewish: The 100-Year War Against TB

by Jeff Bradley and
Michael Iseman, MD
Director, National Jewish Medical and Research Center
Denver, Colorado

National Jewish Medical and Research Center, which celebrated its centennial in 1999, is known today for its expertise in a wide array of respiratory, immunologic, allergic, and infectious diseases. At the time of its founding, however, it had a single purpose: the care of impoverished victims of TB.

The need for a TB hospital became acute in Denver in the 1880s. In those days, people believed that the dry climate of the high plains on which Denver is located would cure tuberculars (i.e., persons with TB disease). Consequently, many TB sufferers spent their last dollars coming to Colorado. By the 1890s, it was estimated that one out of every three residents of the state was there for respiratory reasons.

Image 1: Picture of the Old National Jewish Hospital

In Denver, TB patients were literally dying on the streets. Boarding houses often banned "lungers," as they were called, and many of them were too sick to support themselves. A woman named Frances Wisebart Jacobs recognized the need for a TB hospital and, after joining forces with a young rabbi, the two raised enough money to buy some land and erect a building, which was ready for patients in 1893. Unfortunately, however, Denver was hit with the Silver Crisis that year, and there was not enough money to open and run the hospital.

This setback convinced the organizers that they should expand their fundraising efforts beyond Colorado. The thinking in Denver was that, since patients came there from all over the nation, people all over the United States should help support the hospital. They turned to B'nai B'rith, a national Jewish service organization, and contributions came in from across the country. The building finally opened in 1899 as the "National Jewish Hospital for Consumptives."

National Jewish was the first hospital in the nation to focus exclusively on indigent TB patients. As expressed in a singular motto, this philosophy was "None may enter who can pay, none can pay who enter." From day one, National Jewish was non-profit and non-sectarian.

The hospital opened with a capacity of 60 patients; the goal was to treat 150 patients per year. This was made possible by putting a 6-month limit on patient stays. Furthermore, National Jewish only accepted patients in the early stages of TB. At least that was the plan. In reality, however, several chronic sufferers were admitted, and after a few months, the 6-month limit was lifted.

The treatment at National Jewish was in line with the protocols at other turn-of-the-century TB sanatoria: plenty of fresh air, lots of food, moderate exercise, and close scrutiny of every aspect of patients' lives. The inhabitants of National Jewish, thus, could expect to sleep outside or with their heads outside every night, and were all but stuffed with food. In 1911, for instance, the annual report records that National Jewish spent $3,631 on eggs roughly equivalent to $62,000 today for just 120 patients.

In 1914, National Jewish erected a building for the study of TB; this was the first place in which research on the disease was done outside of a medical school setting. Other advances included the nation's first self-contained facility for treating children with active cases of TB and work on anti-TB drugs such as isoniazid (INH) in the early 1950s. Later in that same decade, doctors at National Jewish came up with a new protocol for TB that included abandonment of bed rest and a substitution of physical activity; use of microbiological assay measurements to determine the proper dosage of INH; and combined drug therapy using streptomycin, INH, and para-aminosalicylic acid.

As TB gradually came under control in the United States, National Jewish expanded its mission to include asthma and other respiratory diseases, but maintained a strong presence in TB. Research continued on better drugs, and the institution expanded its education efforts. In 1963, the 1- to 2-week TB control course was offered for specialists from all over the world, a course that is still offered today. Indeed, over the past 20 years, nearly 5,000 physicians and nurses have visited Denver for the course.

Rifampin, the most widely used drug for TB today, was tested at National Jewish in 1970. Two years later, federal funds established a state-of-the-art laboratory to study difficult TB cases. This helped establish National Jewish as a highly specialized center for drug-resistant TB and atypical mycobacterial infections.

Today, National Jewish continues to be a steady contributor in the fight against TB. The hospital offers compassionate care to victims of MDR TB, often providing treatment for the poor at no charge. Leading pharmaceutical companies collaborate with National Jewish to test new drugs. Perhaps the greatest contribution of National Jewish is in education. In addition to the TB course, the hospital maintains a Mycobacterial Consult Line, a free service whereby physicians anywhere in the world can call up and receive advice from our specialists. Over the past 5 years this service has responded to over 2,000 calls annually.

At the opening of National Jewish back in 1899, the president of the institution, speaking of TB in the exalted rhetoric of that day, declared that it was his dream for the hospital "that its doors may never close again until the terrible scourge is driven from the earth." Now, at the time when the World Health Organization estimates that one out of every three people in the world is infected with TB, those doors are still open.

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333